Imv Inc.
Pagina dedicata companiei Imv Inc. listata cu simbolurile US.IMV, US.IMVc
Descriere companie[edit | ]
IMV Inc. (https://imv-inc.com/) is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer and other medical needs. The Company is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. It is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The Company is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Grafic actiuni companie[edit | ]